Evaluation of the Efficacy of an inTerdialytic "Ethanol 40% v/v - enoxapaRin 1000 U/mL" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Mar 13, 2017
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special solution made of ethanol and a blood thinner called enoxaparin, which is used to help prevent infections in patients who have a tunnelled catheter for hemodialysis. Hemodialysis is a treatment for patients with end-stage kidney disease, where a machine cleans their blood. The researchers want to see if this new solution can help keep the catheter, which is a tube inserted into the body for dialysis, free from infections.
To participate in this study, individuals need to be between 65 and 74 years old, have end-stage kidney disease, and be receiving hemodialysis at least three times a week, with their catheter in place for at least two weeks. Participants will need to provide written consent and have health insurance coverage. If eligible, patients will be part of a study that aims to improve their care and potentially reduce the risk of infections related to their catheters.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • end-stage renal disease
- • chronic hemodialysis/hemodiafiltration at least three times a week
- • functional TC inserted for at least two weeks
- • Social security cover
- • Written informed consent
- Exclusion Criteria:
- • -
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Patients applied
Trial Officials
Julien ANIORT
Principal Investigator
University Hospital, Clermont-Ferrand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials